Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection

Sulkowski MS, Naggie S, Lalezari J, et al. Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. Fessel WJ, Mounzer K, Shuhart M, Luetkemeyer AF, Asmuth D, Gaggar A, et al. JAMA. 2014;312(4):353-361.

Publication Type:

Journal Article

Authors:

M S Sulkowski; Naggie, S.; Lalezari, J.; et, al

Source:

JAMA, Volume 312, Issue 4, p.353-361 (2014)

Keywords:

Administration,Oral, Adult, adverse effects, Aged, analogs & derivatives, Antiretroviral, Antiretroviral Therapy, Antiviral Agents, Baltimore, blood, California, Cities, clinical trial, coinfection, Disease, Drug Administration Schedule, Drug Interactions, drug therapy, Drug Therapy,Combination, eradication, Fatigue, Female, genetics, Genotype, genotype 1, HCV, Headache, Hepacivirus, hepatitis, Hepatitis C, hepatitis C virus, Hiv, HIV Infections, HIV RNA, Human, Humans, Infection, interferon, Internal Medicine, interventions, Liver, Male, Maryland, Medicine, Middle Aged, Multicenter Studies, Nausea, New York, North Carolina, Patients, Philadelphia, Puerto Rico, Research, Research Support, Ribavirin, Rna, Rna,Viral, San Francisco, Serum, sofosbuvir, sustained virologic response, SVR, therapeutic use, therapy, treatment, Treatment Outcome, treatment-naive, United States, Universities, Uridine, Uridine Monophosphate, Viral Load, virology, Washington, Young Adult

Cited On:

External Third-party Web Link:

http://www.ncbi.nlm.nih.gov/pubmed/25038354

Export Citation:
RIS Format
Top